Revvity (RVTY) Gets a Hold From Wells Fargo
Jefferies Maintains Revvity(RVTY.US) With Hold Rating, Raises Target Price to $130
Revvity Initiated at Equal-Weight by Wells Fargo
Revvity Analyst Ratings
Wells Fargo Initiates Coverage On Revvity With Equal-Weight Rating, Announces Price Target of $130
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)
Revvity Price Target Raised to $145.00/Share From $135.00 by Citigroup
TD Cowen Adjusts Price Target on Revvity to $141 From $130
A Quick Look at Today's Ratings for Revvity(RVTY.US), With a Forecast Between $125 to $145
B of A Securities Maintains Neutral on Revvity, Raises Price Target to $127
Revvity's Balanced Performance Amidst Market Challenges: A Hold Recommendation With Updated Price Objective
Barclays Sticks to Their Hold Rating for Revvity (RVTY)
Jefferies Maintains Hold on Revvity, Raises Price Target to $125
Revvity Analyst Ratings
Nephron Adjusts Price Target on Revvity to $134 From $124
Revvity Analyst Ratings
Revvity Analyst Ratings
Barclays Trims Price Target on Revvity to $115 From $116
TD Cowen: Maintaining the Revvity (RVTY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $123.00 to $130.00.
Revvity Analyst Ratings